Core Viewpoint - Bicara Therapeutics Inc. has successfully closed a public offering, raising approximately $172.5 million to support the development and commercialization of its lead therapy, ficerafusp alfa, aimed at treating solid tumors [1][2]. Group 1: Offering Details - The company offered 8,581,250 shares of common stock and pre-funded warrants for 2,200,000 shares at an exercise price of $0.0001 per share [1]. - The public offering price was set at $16.00 per share for common stock and $15.9999 for pre-funded warrants [1]. - The offering included an option exercised in full by underwriters for an additional 1,406,250 shares [1]. Group 2: Use of Proceeds - Net proceeds from the offering will be used to build medical and commercial infrastructure for a planned regulatory filing and commercial launch of ficerafusp alfa in the U.S. [2]. - Funds will also accelerate the development of ficerafusp alfa in first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma, including a less frequent dosing schedule [2]. - Additional uses include covering manufacturing costs for ongoing drug development, early signal-finding for future indication expansion, and general corporate purposes [2]. Group 3: Company Overview - Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors [6]. - The lead program, ficerafusp alfa, is designed to enhance tumor penetration by targeting the tumor microenvironment, combining an EGFR-directed monoclonal antibody with a TGF-β binding domain [6]. - The therapy aims to address significant unmet needs in head and neck squamous cell carcinoma and other solid tumor types [6].
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares